Literature DB >> 29497977

Five-year postsurgical monitoring of serum p53 antibody for locally advanced esophageal squamous cell carcinoma.

Ryosuke Kochi1, Satoshi Yajima1, Tatsuki Nanami1, Takashi Suzuki1, Yoko Oshima1, Natsuki Tokura2, Jun Takatsuka2, Kimihiko Funahashi1, Naobumi Tochigi3, Hideaki Shimada4,5.   

Abstract

Serum p53 antibody (s-p53-Ab) titers were postoperatively monitored for over 5 years in a 67-year-old man with locally advanced esophageal squamous cell carcinoma. The tumor stage was classified as clinical stage II (cT3N0M0). Serum SCC antigen (s-SCC-Ag; 6.2 ng/mL) and s-p53-Ab (3.83 U/mL) were noted to be positive before surgery. Radical esophagectomy with three-field lymph node dissection was performed without neoadjuvant therapy. Pathological findings of the surgically resected specimens revealed a stage II tumor (pT3N0M0). Postoperatively, the patients did not receive any adjuvant therapy. Although the s-SCC-Ag was found to be negative at 2 months postoperatively, s-SCC-Ag was found to be six times positive despite no signs of recurrence. The s-p53-Ab titers constantly decreased to less than the cutoff value at 6 months postoperatively and continuously decreased over 5 years postoperatively. Finally, s-p53-Ab titers became less than the detection limit value at 60 months postoperatively. No recurrence was observed throughout the postoperative course. This case report is the first to describe the five-year monitoring of postoperative changes in s-p53-Ab titers in a patient with locally advanced esophageal squamous cell carcinoma without recurrence. s-p53-Ab titers seemed to be more useful than s-SCC-Ag for disease monitoring in this case.

Entities:  

Keywords:  Antibody titer; Esophageal squamous cell carcinoma; Monitoring; Serum p53 antibody

Mesh:

Substances:

Year:  2018        PMID: 29497977     DOI: 10.1007/s12328-018-0839-3

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  8 in total

1.  The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.

Authors:  Yukiharu Hiyoshi; Naoya Yoshida; Masayuki Watanabe; Junji Kurashige; Yoshifumi Baba; Yasuo Sakamoto; Hideo Baba
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

2.  Peritherapeutic Serum p53 Antibody Titers are Predictors of Survival in Patients with Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemotherapy and Surgery.

Authors:  Kotaro Yamashita; Tomoki Makino; Koji Tanaka; Makoto Yamasaki; Masaaki Yamamoto; Yasuhiro Miyazaki; Tsuyoshi Takahashi; Yukinori Kurokawa; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  World J Surg       Date:  2017-06       Impact factor: 3.352

3.  Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.

Authors:  H Shimada; A Takeda; M Arima; S Okazumi; H Matsubara; Y Nabeya; Y Funami; H Hayashi; Y Gunji; T Suzuki; S Kobayashi; T Ochiai
Journal:  Cancer       Date:  2000-10-15       Impact factor: 6.860

4.  Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery.

Authors:  Kenji Murayama; Tatsuki Nanami; Takashi Suzuki; Yoko Oshima; Satoshi Yajima; Tetsuo Nemoto; Hideaki Shimada
Journal:  Clin J Gastroenterol       Date:  2017-05-24

5.  Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma.

Authors:  Hideaki Shimada; Tooru Shiratori; Akihiko Takeda; Kazuyuki Matsushita; Shinichi Okazumi; Yasunori Akutsu; Hisahiro Matsubara; Fumio Nomura; Takenori Ochiai
Journal:  World J Surg       Date:  2009-02       Impact factor: 3.352

6.  Metabolic properties of IgG subclasses in man.

Authors:  A Morell; W D Terry; T A Waldmann
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

7.  Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.

Authors:  Hideaki Shimada; Takenori Ochiai; Fumio Nomura
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

8.  Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case.

Authors:  Hideaki Shimada; Matsuo Nagata; Akihiro Cho; Nobuhiro Takiguchi; Osamu Kainuma; Hiroaki Soda; Atsushi Ikeda; Yoshihiro Nabeya; Satoshi Yajima; Hiroshi Yamamoto; Takahiro Sugiyama; Makiko Itami
Journal:  Surg Today       Date:  2013-11-17       Impact factor: 2.549

  8 in total
  2 in total

1.  Serum levels of ANOS1 serve as a diagnostic biomarker of gastric cancer: a prospective multicenter observational study.

Authors:  Mitsuro Kanda; Yun-Suhk Suh; Do Joong Park; Chie Tanaka; Sang-Hoon Ahn; Seong-Ho Kong; Hyuk-Joon Lee; Daisuke Kobayashi; Michitaka Fujiwara; Hideaki Shimada; BeLong Cho; Kenta Murotani; Hyung-Ho Kim; Han-Kwang Yang; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2019-08-03       Impact factor: 7.370

2.  Association of APC gene promoter methylation and the risk of gastric cancer: A meta-analysis and bioinformatics study.

Authors:  Xueliang Zhou; Dechao Jiao; Mengmeng Dou; Weijie Zhang; Hao Hua; Jianjian Chen; Zhaonan Li; Lifeng Li; Xinwei Han
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.